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1 |  INTRODUCTION
Lymph node (LN) metastasis in patients with cancer is con-
sidered to be an important predictor of poor prognosis. There 
has been much debate about how tumor cells spread to dis-
tant organs hematogenously via LNs.1-4 Recently, several pa-
pers have reported that metastatic LNs could be the origin 
of systemic metastases.5-7 Brown et al5 determined that high 
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Abstract
Metastatic lymph nodes (LNs) may be the origin of systemic metastases. It will be 
important to develop a strategy that prevents systemic metastasis by treating these 
LNs at an early stage. False‐negative metastatic LNs, which are found during the 
early stage of metastasis development, are those that contain tumor cells but have a 
size and shape similar to LNs that do not host tumor cells. Here, we show that 5‐fluo-
rouracil (5‐FU), delivered by means of a novel lymphatic drug delivery system 
(LDDS), can treat LNs with false‐negative metastases in a mouse model. The effects 
of 5‐FU on four cell lines were investigated using in vitro cytotoxicity and cell sur-
vival assays. The therapeutic effects of LDDS‐administered 5‐FU on false‐negative 
metastatic LNs were evaluated using bioluminescence imaging, high‐frequency ul-
trasound (US), and histology in MHX10/Mo‐lpr/lpr mice. These experimental ani-
mals develop LNs that are similar in size to human LNs. We found that all cell lines 
showed sensitivity to 5‐FU in the in vitro assays. Furthermore, a concentration‐de-
pendent effect of 5‐FU to inhibit tumor growth was observed in tumor cells with low 
invasive growth characteristics, although a significant reduction in metastatic LN 
volume was not detected in MHX10/Mo‐lpr/lpr mice. Adverse effects of 5‐FU were 
not detected. 5‐Fluorouracil administration with a LDDS is an effective treatment 
method for false‐negative metastatic LNs. We anticipate that the delivery of antican-
cer drugs by a LDDS will be of great benefit in the prevention and treatment of can-
cer metastasis via LNs.
K E Y W O R D S
false‐negative, fluorouracil (5‐FU), lymph node, lymphatic drug delivery system, metastasis, mouse
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endothelial venules play an important role in hematogenous 
metastasis, and Pereira et al7 concluded that tumor cells in-
vade local vessels in LNs and that this is followed by he-
matogenous metastasis. Kodama et al6 demonstrated that the 
initiation of hematogenous metastasis is tumor cell invasion 
from the marginal sinus of a LN into the extranodal veins, 
and the authors advocated the theory of LN‐mediated hema-
togenous metastasis.6,8,9 Several clinical trials have indicated 
that surgical excision of tumor‐draining LNs has no effect 
on the long‐term survival of patients with cancer.10-12 These 
findings suggest that tumor cells are seeded throughout the 
body at the stage where micrometastasis exists in the LNs, 
and as a result, surgical dissection does not affect the long‐
term survival of cancer patients; this result would support the 
validity of the LN‐mediated hematogenous metastasis theory.
Although the theory of LN‐mediated hematogenous me-
tastasis needs confirmation in a clinical setting, it is clear that 
a new strategy is required that prevents systemic metastasis 
by treating metastatic LNs at the early stage of metastasis. 
Since LNs have a rich vascular network,13 tumor cells can 
develop in them without tumor angiogenesis.14,15 Thus, he-
matogenous delivery of macromolecular drugs based on the 
enhanced permeability and retention effect16 and normal-
ization of the circulation (ie, improvement of the flow and 
functions of the vasculature)17 would not be effective in the 
treatment of metastatic LNs. In addition, the lymphatic sys-
tem preferentially takes up large‐sized particles and high 
molecular weight substances. Particles 10‐100 nm in size 
are reabsorbed from the interstitial space by the lymphatic 
system,18,19 while those < 10 nm in size are primarily re-
absorbed by blood vessels. The efficiency of reabsorption 
into the lymphatic system correlates positively with molec-
ular weight, and substances with a molecular weight above 
16 000 g/mol are mainly taken up by the lymphatic sys-
tem.20,21 Since anticancer drugs are usually small molecules, 
generally they are poorly delivered to the lymphatic system 
after systemic administration.
For the above reasons, the use of a LDDS to deliver an-
ticancer drugs efficiently to false‐negative metastatic LNs 
during the early stage of metastasis has been proposed.22 
False‐negative metastatic LNs are those that contain tumor 
cells but, due to the early stage of tumor development, have 
a size and shape similar to those of LNs not hosting tumor 
cells. The LDDS is a new approach to treat or prevent LN 
micrometastasis, and we have previously demonstrated this 
novel therapeutic concept.23 The LDDS operates by injecting 
drugs into sentinel (upstream) LNs in order to deliver them 
to downstream metastatic LNs in the lymphatic network and 
maintain high concentrations of drug within the targeted LNs.
The aim of this investigation was to examine the therapeu-
tic effects of 5‐FU administered through a LDDS on false‐
negative metastatic LNs. 5‐Fluorouracil has been widely 
used to treat LN metastasis in breast and gastric cancer. First, 
the antitumor effects of 5‐FU were assessed in four different 
cell lines using in vivo cytotoxicity and cell survival assays. 
Next, mouse models of LN metastasis (generated using two 
tumor cell lines with different growth characteristics) were 
utilized to evaluate the therapeutic effects of LDDS‐admin-
istered 5‐FU on false‐negative metastatic LNs. It was found 
that by using a LDDS, the administration of 5‐FU is an effec-
tive treatment for LNs with false‐negative metastases.
2 |  METHODS
The Tohoku University Institutional Animal Care and Use 
Committee approved the in vivo study protocols.
2.1 | Culture of cells
Cultured cells used in the experiments were MRL/
MpTn‐gld/gld mouse malignant KM‐Luc/GFP cells that 
stably expressed a fusion of the enhanced‐green fluorescent 
protein and luciferase genes were maintained in culture,24 
as were BALB/cCrgl mouse mammary carcinoma cells 
(EMT6‐Luc) that stably expressed the firefly luciferase 
gene,25 C3H/He mouse Dunn osteosarcoma cells (LM8‐
Luc) stably expressing the firefly luciferase gene,26 and 
C3H/He mouse mammary carcinoma cells (FM3A‐Luc) 
stably expressing the Luc gene.27 KM‐Luc/GFP, EMT6‐Luc 
and LM8 cells were cultured in Dulbecco's modified Eagle's 
medium (DMEM; Sigma‐Aldrich, St Louis, MO) supple-
mented with 10% heat‐inactivated fetal bovine serum (FBS; 
HyClone Laboratories Inc., UT, US) and 1% l‐glutamine–
penicillin‐streptomycin (Sigma‐Aldrich). FM3A‐Luc cells 
were maintained in RPMI‐1640 medium supplemented with 
10% (v/v) FBS (HyClone Laboratories Inc.), 1% (v/v) l‐glu-
tamine–penicillin‐streptomycin and 1 mg/mL G418 (Wako 
Pure Chemical Industries, Osaka, Japan). Cell lines were 
incubated at 37°C in an atmosphere of 5% CO2 and 95% air 
until 80% confluence was achieved. A lack of Mycoplasma 
contamination was confirmed for all in vivo experiments 
on the inoculation day using a MycoAlert Mycoplasma 
Detection Kit (Lonza Rockland, ME, US).
2.2 | In vitro cytotoxicity and cell 
survival assays
The cytotoxic effects of 5‐FU on KM‐Luc/GFP cells (n = 8) 
and FM3A‐Luc cells (n = 8) in 96‐well plates were measured 
using a lactate dehydrogenase (LDH) assay according to the 
protocol provided by the kit manufacturer (LDH‐cytotoxicity 
kit; Wako Pure Chemical Industries). The cytotoxicity ratio 
was calculated thus:
(1)Cytotoxicity ratio (%)=
S−N
P−N
×100
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where S is the mean absorbance of the wells to which 5‐
FU was added, N the average absorbance of negative control 
wells, and P the average absorbance of positive control wells. 
The MTT assay was carried out for KM‐Luc/GFP (n = 12), 
FM3A‐Luc (n = 12), EMT6‐Luc (n = 7), and LM8‐Luc 
(n = 8) cells in 96‐well plates, as previously described.28 The 
cell survival ratio was determined by the following equation:
where Ax is the average absorbance of the wells to which 
5‐FU was added and A0 the average absorbance of the wells 
without 5‐FU.
2.3 | Mice
MHX10/Mo‐lpr/lpr (MXH10/Mo/lpr) mice (aged 
16‐18 weeks)27 were bred under specific pathogen‐free con-
ditions in the Animal Research Institute, Tohoku University. 
MXH10/Mo/lpr mice are exceptional in that their peripheral 
LNs develop to 10 mm in size at 2.5 to 3 months, and they 
do not exhibit autoimmune disease. In the present study, we 
used the term “subiliac LN” instead of “inguinal LN”29 to 
assign the correct anatomical locations and nomenclatures to 
murine LNs.
2.4 | Induction of metastasis in the proper 
axillary LN (PALN) by injection of tumor cells 
into the subiliac LN (SiLN)
Mice were anesthetized (2% isoflurane in O2), and the 
unilateral SiLN injected (under US guidance) with KM‐
Luc/GFP cells (3.3 × 105 cells/mL) or FM3A‐Luc cells 
(3.3 × 105 cells/mL) suspended in 10 μL phosphate‐buff-
ered saline plus 20 μL of 400 mg/mL Matrigel (Collaborative 
Biomedical Products, Bedford, MA). Tumor cells were in-
jected into the SiLN to induce metastasis in the PALN. The 
day of tumor cell inoculation was defined as day 0.23 Tumor 
growth in the PALN was assessed with an in vivo biolu-
minescence imaging system (IVIS; PerkinElmer, Waltham, 
MA, US). Luciferase activity was measured on day 3, day 
6, and day 9 for KM‐Luc/GFP cells. Metastasis of the 
PALN was considered to have occurred when the luciferase 
activity exceeded the background level in controls (2 × 105 
photons/s) on day 6. The day on which PALN metastasis 
was confirmed was defined as day 0T. For FM3A‐Luc cells, 
PALN tumor growth was assessed on day 7, day 14, and 
every 3 days after day 14. PALN metastasis was considered 
to have occurred when the luciferase activity exceeded the 
background level in controls (1 × 106 photons/s). The day 
on which PALN metastasis was confirmed was defined as 
day –1T.
2.5 | Treatment of the metastatic PALN 
with 5‐FU
Mice with confirmed metastasis of KM‐Luc/GFP cells to the 
PALN were randomly divided into four groups based on the 
concentration of 5‐FU administered: control (saline alone, ie, 
0 μg/g; n = 4), 0.1 μg/g (n = 4), 1 μg/g (n = 4), and 10 μg/g 
(n = 4). Mice with confirmed metastasis of FM3A‐Luc cells 
to the PALN were randomly divided into five groups thus: 
control (saline alone, ie, 0 μg/g; n = 6), 0.1 μg/g (n = 5), 
1 μg/g (n = 5), 10 μg/g (n = 5), and 100 μg/g (n = 5). Each 
mouse was deeply anesthetized with 2% isoflurane (Abbott 
Japan, Chiba, Japan) in O2, and 120 μL of the appropriate 
solution was injected into the accessory axillary LN (AALN). 
Injection of 5‐FU solution into the AALN was carried out with 
a 27‐G butterfly needle at an injection speed of 10 μL/min 
using a syringe pump (Legato100; KD Scientific, Holliston, 
MA, US) under the guidance of a high‐frequency ultrasound 
imaging system (VEVO770; VisualSonics, Toronto, Canada) 
with a 25‐MHz transducer (RMV‐710B; axial resolution, 
70 μm; focal length, 15 mm; VisualSonics) on day 0T.
2.6 | Measurement of SiLN and 
PALN volumes
SiLN and PALN volumes were measured using a high‐fre-
quency ultrasound imaging system (VEVO770; Visual Sonics) 
with a 25‐MHz transducer (RMV‐710B; Visual Sonics) on day 
0 (ie, ‐6T), day 6 (ie, 0T), and day 9 (ie, 3T) for KM‐Luc/GFP 
cells and on day 0, day 0T, and day 9T for FM3A‐Luc cells.
2.7 | Ex vivo measurement of tumor growth
The PALN was harvested on day 3T for KM‐Luc/GFP cells and 
on day 9T for FM3A‐Luc cells. Luciferase activity in the sam-
ples (in six‐well plates) was measured with the IVIS (0.3 mg/
mL luciferin). Luciferase activity was evaluated on both sides 
of each sample to obtain the average luciferase activity.
2.8 | Blood biochemistry to assess renal/
hepatic toxicity of 5‐FU
Mice were assigned into five groups based on the tumor cell 
line and 5‐FU concentration used thus: KM‐Luc/GFP, 0 μg/g 
(n = 4); KM‐Luc/GFP, 10 μg/g (n = 4); FM3A‐Luc, 0 μg/g 
(n = 6); FM3A‐Luc, 10 μg/g (n = 5); and FM3A‐Luc, 100 μg/g 
(n = 5). Blood was drawn from the left ventricle on day 3T 
(KM‐Luc/GFP) or day 9T (FM3A‐Luc), and plasma was ob-
tained by centrifugation at 13 000 g for 10 seconds. Hepatic 
and renal functions were evaluated from plasma measurements 
of total bilirubin (T‐BIL), alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), creatinine (Cre), and blood 
urea nitrogen (BUN) (Oriental Yeast, Tokyo, Japan).
(2)Cell survival ratio (%)= Ax
A0
×100
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2.9 | Weight measurement
To evaluate any acute toxic effects of 5‐FU, the body weights 
of mice were measured and recorded. For mice inoculated with 
KM‐Luc/GFP cells, body weights were measured on days 0, 3, 
6 (0T), and 9 (3T). For mice inoculated with FM3A‐Luc cells, 
body weights were measured on days 0, ‐1T, 0T, 3T, 6T, and 9T.
2.10 | Histological analysis
Tissues (PALN, AALN, lung, liver, and kidney) were ex-
cised on day 3T (KM‐Luc/GFP) or day 9T (FM3A‐Luc), fixed 
overnight in 10% formalin at 4°C, dehydrated, embedded in 
paraffin, serially sectioned (3‐4 μm), and either stained with 
hematoxylin and eosin (H&E) or immunostained for LYVE‐1‐
positive and CD31‐positive cells (Discovery XT Automated 
Staining Processor; Ventana Medical Systems, Tucson, AZ).30
2.11 | Statistical analysis
All data are expressed as the mean ± standard error of 
the mean (SEM) or the mean ± standard deviation (SD). 
Statistical analysis was performed using a one‐way repeated‐
measures ANOVA, two‐way repeated‐measures ANOVA, 
Kruskal‐Wallis test, Tukey test, or an unpaired t‐test as ap-
propriate. A value of P < 0.05 was considered to be a statisti-
cally significant difference.
3 |  RESULTS
3.1 | In vitro cytotoxicity assay
The measurement of the cell survival ratio by the MTT 
assay demonstrated that 5‐FU caused a concentration‐de-
pendent decrease in the viability of all four tumor cell 
lines (Figure 1A). For KM‐Luc/GFP cells, a statisti-
cally significant decrease in cell viability was observed 
F I G U R E  1  In vitro cytotoxicity and cell survival in the 
presence of 5‐fluorouracil (5‐FU). (A) Cell survival ratio determined 
by the MTT assay. 5‐Fluorouracil elicited a concentration‐dependent 
reduction in cell viability in all cell lines. In KM‐Luc/GFP cells, 
a statistically significant decrease in cell viability was observed 
for 1 μmol/L, 10 μmol/L, 100 μmol/L, and 1000 μmol/L 5‐FU 
(***P < 0.001, 10 μmol/L vs 0 μmol/L, 100 μmol/L vs 0 μmol/L, and 
1000 μmol/L vs 0 μmol/L; *P < 0.05, 1 μmol/L vs 0 μmol/L; one‐
way ANOVA and Dunnett's test). In FM3A‐Luc cells, a statistically 
significant decrease in cell viability was observed for all concentrations 
of 5‐FU tested (***P < 0.001, 1 μmol/L vs 0 μmol/L, 10 μmol/L vs 
0 μmol/L, 100 μmol/L vs 0 μmol/L, and 1000 μmol/L vs 0 μmol/L; 
*P < 0.05, 0.1 μmol/L vs 0 μmol/L; one‐way ANOVA and Dunnett's 
test). In EMT6‐Luc cells, statistically significant decreases in cell 
viability were observed for 1 μmol/L, 10 μmol/L, 100 μmol/L, 
and 1000 μmol/L 5‐FU (***P < 0.001, 1000 μmol/L vs 0 μmol/L; 
**P < 0.01, 10 μmol/L vs 0 μmol/L, and 100 μmol/L vs 0 μmol/L; 
*P < 0.05, 1 μmol/L vs 0 μmol/L; one‐way ANOVA and Dunnett's 
test). In LM8‐Luc cells, statistically significant decreases in cell 
viability were observed for 1 μmol/L, 10 μmol/L, 100 μmol/L, and 
1000 μmol/L 5‐FU (***P < 0.001, 1 μmol/L vs 0 μmol/L, 10 μmol/L 
vs 0 μmol/L, 100 μmol/L vs 0 μmol/L, and 1000 μmol/L vs 0 μmol/L; 
one‐way ANOVA and Dunnett's test). For each well, the MTT assay 
was repeated three times for KM‐Luc/GFP and FM3A‐Luc cells, 
and twice for EMT6‐Luc and LM8‐Luc cells. Data are presented as 
the mean ± SD (number of wells: KM‐Luc/GFP, n = 12; FM3A‐
Luc, n = 12; EMT6‐Luc, n = 7; LM8‐Luc, n = 8). (B) Cytotoxicity 
measured using the LDH assay. 5‐Fluorouracil had only weak cytotoxic 
actions in KM‐Luc/GFP and FM3A‐Luc cells. In KM‐Luc/GFP cells, 
a statistically significant increase in the cytotoxicity ratio was observed 
for 1000 μmol/L 5‐FU (***P < 0.001, 1000 μmol/L vs 0 μmol/L; one‐
way ANOVA and Dunnett's test). In FM3A‐Luc cells, a statistically 
significant increase in the cytotoxicity ratio was observed for 1 μmol/L, 
100 μmol/L, and 1000 μmol/L 5‐FU (***P < 0.001, 1 μmol/L vs 
0 μmol/L, 100 μmol/L vs 0 μmol/L, and 1000 μmol/L vs 0 μmol/L; 
one‐way ANOVA and Dunnett's test). The LDH assay was performed 
in triplicate for each experiment (ie, each well). Data are presented as 
the mean ± SD (number of wells: KM‐Luc/GFP, n = 8; FM3A‐Luc, 
n = 9)
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at 1 μmol/L, 10 μmol/L, 100 μmol/L, and 1000 μmol/L 
5‐FU (P < 0.001, 10 μmol/L vs 0 μmol/L, 100 μmol/L 
vs 0 μmol/L, and 1000 μmol/L vs 0 μmol/L; P < 0.05, 
1 μmol/L vs 0 μmol/L; one‐way ANOVA and Dunnett's 
test). For FM3A‐Luc cells, statistically significant decreases 
in the cell survival ratio were observed at all concentrations 
of 5‐FU (P < 0.001, 1 μmol/L vs 0 μmol/L, 10 μmol/L vs 
0 μmol/L, 100 μmol/L vs 0 μmol/L and 1000 μmol/L vs 
0 μmol/L; P < 0.05, 0.1 μmol/L vs 0 μmol/L; one‐way 
ANOVA and Dunnett's test). In EMT6‐Luc cells, 5‐FU 
concentrations of 1 μmol/L, 10 μmol/L, 100 μmol/L, and 
1000 μmol/L elicited statistically significant decreases 
in cell viability (P < 0.001, 1000 μmol/L vs 0 μmol/L; 
P < 0.01, 10 μmol/L vs 0 μmol/L and 100 μmol/L vs 
0 μmol/L; P < 0.05, 1 μmol/L vs 0 μmol/L). In LM8‐Luc 
cells, statistically significant decreases in cell viability 
were observed at 1 μmol/L, 10 μmol/L, 100 μmol/L, and 
1000 μmol/L 5‐FU (P < 0.001, 1 μmol/L vs 0 μmol/L, 
10 μmol/L vs 0 μmol/L, 100 μmol/L vs 0 μmol/L, and 
1000 μmol/L vs 0 μmol/L).
Since KM‐Luc/GFP and FM3A‐Luc cells have been 
confirmed to engraft in mice in previous research, these 
two cell lines were chosen for further experiments. The 
LDH assay revealed that 5‐FU exerted only minor cy-
totoxic effects on KM‐Luc/GFP and FM3A‐Luc cells 
(Figure 1B). For KM‐Luc/GFP cells, a statistically signif-
icant increase in the cytotoxicity ratio was observed for 
1000 μmol/L 5‐FU (P < 0.001, 1000 μmol/L vs 0 μmol/L; 
one‐way ANOVA and Dunnett's test). In FM3A‐Luc cells, 
a statistically significant increase in the cytotoxicity ratio 
was observed for 1 μmol/L, 100 μmol/L, and 1000 μmol/L 
5‐FU (P < 0.001, 1 μmol/L vs 0 μmol/L, 100 μmol/L vs 
0 μmol/L, and 1000 μmol/L vs 0 μmol/L; one‐way ANOVA 
and Dunnett's test).
3.2 | Measurements of PALN volume 
before and after the occurrence of metastasis
To confirm that the present animal model was suitable 
for the study of false‐negative metastatic LNs, a high‐fre-
quency ultrasound imaging system was used to compare 
PALN volumes before (day 0) and after (day 0T) the in-
duction of metastasis. Figure 2A shows that there was no 
significant increase in PALN volume between day 0 (–6T, 
n = 13) and day 0T (n = 13) when KM‐Luc/GFP cells were 
used to induce metastasis. As shown in Figure 2B, PALN 
volume decreased significantly between day 0 (n = 26) and 
day 0T (n = 26) when FM3A‐Luc cells were used to induce 
metastasis (P < 0.05, day 0 vs day 0T; paired t test). The 
absence of an increase in PALN volume after the induction 
of metastasis with KM‐Luc/GFP or FM3A‐Luc cells con-
firmed that, in both cases, the PALN was a false‐negative 
metastatic LN.
3.3 | Treatment of a false‐negative 
metastatic LN using 5‐FU administered by 
a LDDS
Luciferase activity was measured to evaluate tumor size 
before and after the administration of 5‐FU with a LDDS. 
Luciferase activity was determined on days –3T, 0T, and 3T 
for KM‐Luc/GFP cells (Figure 3A) and days –1T, 3T, 6T, 
and 9T for FM3A‐Luc cells (Figure 3C). Figure 3B shows 
the luciferase activity of KM‐Luc/GFP cells on day 3T nor-
malized to that on day 0T, and Figure 3D shows the lucif-
erase activity of FM3A‐Luc cells on day 9T normalized to 
that on day –1T. When KM‐Luc/GFP cells were used to 
induce metastasis, administration of 10 μg/g 5‐FU resulted 
in a significant decrease in luciferase activity compared 
with the control group (P < 0.05, 10 μg/g vs 0 μg/g; one‐
way ANOVA and Kruskal‐Wallis test). There was also a 
tendency toward a decrease in luciferase activity after the 
delivery of 0.1 μg/g or 1 μg/g 5‐FU, although statistical 
significance was not attained (Figure 3B). When FM3A‐
Luc cells were used, there were no significant reductions 
in luciferase activity for any of the 5‐FU concentrations 
tested (Figure 3D).
F I G U R E  2  PALN volume before and after the induction of 
metastasis. (A) PALN volume before the induction of metastasis on 
day 0 (–6T, n = 13) and after the induction of metastasis with KM‐
Luc/GFP cells on day 0T (n = 13). There was no significant change in 
PALN volume between day 0 and day 0T (NS: not significant; paired 
t test). Data are presented as the mean ± SD. (B) PALN volume prior 
to metastasis on day 0 (n = 26) and after the induction of metastasis 
with FM3A‐Luc cells on day 0T (n = 26). A significant decrease 
in the PALN volume was observed on day 0T compared with day 0 
(*P < 0.05, day 0 vs day 0T; paired t test). Data are presented as the 
mean ± SD
Day 0 Day 0T
Day 0 Day 0T
A KM-Luc/GFP
B FM3A-Luc
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3.4 | Changes in the volumes of the PALN and 
AALN after 5‐FU administration with a LDDS
Changes in AALN and PALN volumes (assessed using a high‐
frequency ultrasound imaging system) were used to evaluate 
the antitumor effect of 5‐FU. Figure 4A‐D show results for 
experiments using KM‐Luc/GFP cells. Figure 4A and B show 
representative images of the AALN and PALN on day 0T and 
day 3T for 5‐FU concentrations of 0 μg/g (control) and 10 μg/g. 
Figure 4C and D show AALN and PALN volumes, respec-
tively, normalized to the volume on day 0T: there were no sig-
nificant differences between the groups. Figure 4E‐H present 
data for experiments that used FM3A‐Luc cells. Figures 4E 
and F show representative images of the AALN and PALN on 
day 0T and day 9T for 5‐FU concentrations of 0 μg/g (control) 
and 100 μg/g. Figure 4G and H shown AALN and PALN 
volumes normalized to the volume on day 0T. AALN volume 
was significantly greater in the 10 μg/g group than in the con-
trol group (P < 0.05, 10 μg/g vs 0 μg/g; one‐way ANOVA 
and Kruskal‐Wallis test), although no significant changes in 
AALN volumes were observed for other concentrations of 5‐
FU (Figure 4G). There were no significant differences in the 
PALN volume between groups (Figure 4H).
3.5 | Ex vivo assessment of the antitumor 
effect of 5‐FU
Figure 5 shows representative ex vivo bioluminescence im-
ages of the PALN for each group (ie, each 5‐FU concentra-
tion). In vivo bioluminescence intensity was measured on 
F I G U R E  3  In vivo bioluminescence imaging of luciferase activity before and after the administration of 5‐fluorouracil (5‐FU) using a 
lymphatic drug delivery system (LDDS). (A) Representative images showing luciferase activity of KM‐Luc/GFP cells in the mouse model of 
LN metastasis. Luciferase activity was measured on days –3T, 0T, and 3T. (B) Luciferase activity on day 3T normalized to that on day 0T. Mice 
administered 10 μg/g 5‐FU exhibited a significant decrease in luciferase activity when compared with controls (*P < 0.05, 10 μg/g vs 0 μg/g; 
one‐way ANOVA and Kruskal‐Wallis test). Although there were trends toward a decrease in luciferase activity in the groups treated with 0.1 μg/g 
and 1 μg/g 5‐FU, statistical significance was not attained (NS: not significant). Data are presented as the mean ± SD (n = 4 for each group). (C) 
Representative images showing luciferase activity of FM3A‐Luc cells in the mouse model of LN metastasis. Luciferase activity was measured on 
days ‐1T, 3T, 6T, and 9T. (D) Luciferase activity on day 9T normalized to that on day ‐1T. Compared with the control group, there were no significant 
decreases in luciferase activity for any of the 5‐FU concentrations tested (NS: not significant; one‐way ANOVA and Kruskal‐Wallis test). Data are 
presented as the mean ± SD (0 μg/g, n = 6; 0.1 μg/g, n = 5; 1 μg/g, n = 5; 10 μg/g, n = 5; 100 μg/g, n = 5)
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day 3T for KM‐Luc/GFP cells and day 9T for FM3A‐Luc 
cells. The PALN was then excised to permit measurements of 
ex vivo bioluminescence intensity. There were no significant 
differences in ex vivo bioluminescence intensity between 
the control group and each 5‐FU group for both KM‐Luc/
GFP cells (Figure 5A and B; one‐way ANOVA and Kruskal‐
Wallis test) and FM3A‐Luc cells (Figure 5C and D; one‐way 
ANOVA and Kruskal‐Wallis test).
3.6 | Blood biochemistry and animal weight
To determine whether the use of the LDDS was associ-
ated with toxicity, blood biochemical parameters on day 
3T (KM‐Luc/GFP cells) and day 9T (FM3A‐Luc cells), and 
changes in animal weight during the study were assessed. 
There were no significant changes in biochemical parameters 
or body weight for both cell lines (Table 1).
3.7 | Histological analysis of the PALN
Figure 6 shows histological analysis of the PALN after the 
administration of 5‐FU with the LDDS. In experiments using 
KM‐Luc/GFP cells, tumor cells were detected in and near 
the marginal sinus in the control group (Figure 6A‐C), with 
tumor cells located near the lymphatic sinus and blood ves-
sels (arrows in Figure 6B and C). In the 10 μg/g 5‐FU group, 
F I G U R E  4  Changes in the volume of the proper axillary lymph node (PALN) and accessory axillary lymph node (AALN) after 5‐
fluorouracil (5‐FU) administration with a lymphatic drug delivery system (LDDS). A, B, C, D: KM‐Luc/GFP cells. E, F, G, H: FM3A‐Luc cells. 
A, Representative 2D ultrasound images of the AALN on day 0T and day 3T. B, Representative 2D ultrasound images of the PALN on day 0T and 
day 3T. C, AALN volume normalized to that on day 0T. There were no significant differences between groups (0 μg/g, 0.1 μg/g, 1 μg/g, and 10 μg/g 
5‐FU; NS: not significant; one‐way ANOVA and Kruskal‐Wallis test). D, PALN volume normalized to that on day 0T. There were no significant 
differences between groups (0 μg/g, 0.1 μg/g, 1 μg/g, and 10 μg/g 5‐FU; NS: not significant; one‐way ANOVA and Kruskal‐Wallis test). Data are 
presented as the mean ± SEM (0 μg/g, n = 3; 0.1 μg/g, n = 3; 1 μg/g, n = 4; 10 μg/g, n = 3). E, Representative 2D ultrasound images of the AALN 
on day 0T and day 9T. F, Representative 2D ultrasound images of the PALN on day 0T and day 9T. G, AALN volume normalized to that on day 
0T. AALN volume was significantly greater in the 10 μg/g 5‐FU group than in the control group (*P < 0.05, 10 μg/g vs 0 μg/g; one‐way ANOVA 
and Kruskal‐Wallis test). H, PALN volume normalized to that on day 0T. There were no significant differences between groups (0 μg/g, 0.1 μg/g, 
1 μg/g, and 10 μg/g 5‐FU; NS: not significant; one‐way ANOVA and Kruskal‐Wallis test). Data are presented as the mean ± SEM (0 μg/g, n = 6; 
0.1 μg/g, n = 5; 1 μg/g, n = 5; 10 μg/g, n = 5; 100 μg/g, n = 5)
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tumor‐containing regions were not detected (Figure 6D‐F). In 
experiments utilizing FM3A‐Luc cells, a tumor‐containing re-
gion was detected in the lymphatic sinus (Figure 6H and K) but 
not blood vessels (Figure 6I and L) in both the groups.
4 |  DISCUSSION
Lymph node metastasis occurs in many carcinomas, and its 
treatment improves the prognosis of patients. Lymph node 
metastasis has been thought to result from tumor cells break-
ing off from the primary tumor to enter the lymphatic ves-
sels and pass through a series of LNs before reaching the 
thoracic duct and subclavian vein.31 Recently, the theory of 
LN‐mediated hematogenous metastasis was advocated,6,9 
suggesting that tumor cell invasion from the marginal sinus 
into extranodal veins during early stage LN metastasis could 
be the starting point for hematogenous metastasis.6 In other 
words, systemic metastasis could potentially be prevented by 
treating false‐negative metastatic LNs. Furthermore, there 
is evidence that dormant cancer cells may be activated by 
surgical dissection of LNs in patients32,33 and in a mouse 
model.34-36 These findings question whether conventional 
LN dissection contributes substantially to an improvement in 
the prognosis of patients.
The present study first explored the cytotoxic effects of 5‐
FU in vitro and then evaluated the therapeutic effects of 5‐FU 
administered by a LDDS in a mouse model of a false‐nega-
tive metastatic LN, which was developed using two differ-
ent tumor cell lines (KM‐Luc/GFP and FM3A‐Luc cells). In 
vitro experiments revealed that four different cell lines were 
sensitive to increasing concentrations of 5‐FU (Figure 1). In 
F I G U R E  5  Ex vivo assessment of the antitumor effect of 5‐fluorouracil (5‐FU). A, B: KM‐Luc/GFP cells. C, D: FM3A‐Luc cells. A, C: 
Representative ex vivo bioluminescence images of the proper axillary lymph node (PALN) for each group (ie, each concentration of 5‐FU) on day 
3T for KM‐Luc/GFP cells (A) and day 9T for FM3A‐Luc cells (C). B, D: Ex vivo bioluminescence intensity for KM‐Luc/GFP cells (B) and FM3A‐
Luc cells (D). There were no significant differences in ex vivo bioluminescence intensity between the control group and each 5‐FU group for both 
KM‐Luc/GFP cells and FM3A‐Luc cells (NS: not significant; one‐way ANOVA and Kruskal‐Wallis test). Data are presented as the mean ± SEM 
(0 μg/g, n = 6; 0.1 μg/g, n = 5; 1 μg/g, n = 5; 10 μg/g, n = 5; 100 μg/g, n = 5)
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vivo experiments in MXH10/Mo/lpr mice demonstrated a 
significant antitumor effect of 5‐FU against KM‐Luc/GFP 
cells but not FM3A‐Luc cells (Figures 3-6). This discrepancy 
may reflect differences in the invasion patterns of the two cell 
types. KM‐Luc/GFP cells have low invasive growth charac-
teristics and form tumor regions with well‐defined borders 
T A B L E  1  Evaluation of the acute toxicity of 5‐FU
 KM‐Luc/GFP FM3A‐Luc
 0 μg/g (n = 4)a 10 μg/g (n = 4)a 
Statistical 
signifi-
canceb 0 μg/g (n = 6)a 10 μg/g (n = 5)a 100 μg/g (n = 5)a 
Statistical 
significancec 
CRE (mg/dL) 0.10 ± 0.01 0.10 ± 0.01 NS 0.08 ± 0.02 0.09 ± 0.01 0.09 ± 0.02 NS
BUN (mg/dL) 26.6 ± 3.4 34.4 ± 15.9 NS 34.1 ± 10.3 32.8 ± 9.7 32.5 ± 5.3 NS
T‐BIL (IU/L) 0.04 ± 0.03 0.02 ± 0.01 NS 0.04 ± 0.03 0.13 ± 0.18 0.03 ± 0.02 NS
AMY (IU/L) 2001.0 ± 88.3 2275 ± 741.8 NS 2115.3 ± 391.8 2302.4 ± 647.5 2117.2 ± 180.0 NS
ALT (IU/L) 37.5 ± 6.2 44.3 ± 12.0 NS 51.0 ± 15.1 66.8 ± 43.1 35.2 ± 6.5 NS
AST (IU/L) 127.0 ± 32.3 115.3 ± 19.1 NS 144.2 ± 37.1 157.8 ± 66.2 122.2 ± 21.8 NS
Weight change (g) −1.00 ± 1.22 −0.25 ± 0.43 NS −1.00 ± 2.94 1.60 ± 1.36 0.40 ± 0.80 NS
Samples were obtained on day 3T for KM‐Luc/GFP cells and on day 9T for FM3A‐Luc cells.
CRE, creatinine; BUN, blood urea nitrogen; T‐BIL, total bilirubin; AMY, amylase ; ALT, alanine aminotransferase; AST, aspartate aminotransferase; NS, not significant.
aValues are mean ± SEM. 
bUnpaired t test. 
cKruskal‐Wallis test. 
F I G U R E  6  Histological analysis of 
the proper axillary lymph node (PALN). 
A‐F: KM‐Luc/GFP cells. In the control 
group (A‐C), tumor cells were detected 
in and near the marginal sinus and in the 
vicinity of the lymphatic sinus (arrows) and 
blood vessels (arrow heads). In the 10 μg/g 
5‐fluorouracil (5‐FU) group (D‐F), a region 
containing tumor cells was not detected. 
G‐L: FM3A‐Luc cells. In both the control 
group (G‐I) and 10 μg/g 5‐FU group (J‐L), 
tumor was detected in the lymphatic sinus 
(H, K) but not in blood vessels (I, L). A, D, 
G, J: HE staining. B, E, H, K: anti‐LYVE‐1 
staining. C, F, I, L: anti‐CD31 staining. T: 
tumor. Scale bar: 100 μm
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in or near the marginal sinuses (Figs 6A‐D).24 On the other 
hand, FM3A‐Luc cells have high invasive growth character-
istics, proliferate along the trabecular sinus, and invade the 
cortex and paracortex (Figs 6I‐P).37 Drugs delivered from the 
AALN to the PALN likely reached KM‐Luc/GFP cells prolif-
erating in the marginal sinus but not FM3A‐Luc cells invading 
the trabecular sinus and cortex. Under normal physiological 
conditions, about 90% of lymph flows into a peripheral path 
via the marginal and medullary sinuses,38 that is, drugs in the 
marginal and medullary sinuses are washed out by lymph.39 
For this reason, a LDDS needs to deliver drugs into the me-
dulla of a metastatic LN. Although physicochemical proper-
ties such as particle size, composition, dose, surface charge, 
and molecular weight are considered to be important factors 
determining the in vivo behavior of particulates, another fac-
tor facilitating the delivery of a drug to a downstream LN 
is the rate of drug injection into an upstream LN. We found 
that intranodal injection of a drug into an upstream LN at a 
rate < 100 μL/min allowed downstream LNs to accumulate 
the drug40 and this efficacy was explained by the impulse val-
ues calculated from injection pressures in the upstream LN.
The present study used MXH10/Mo/lpr mice, which show 
systemic lymphadenopathy from 8 weeks of age due to the 
accumulation of lpr‐T cells.41 MXH10/Mo/lpr mice do not 
express the fas gene involved in apoptosis, since the lpr gene 
is a fas‐deletion mutant gene. Thus, the immune system in 
MXH10/Mo/lpr mice is functional except for the signaling 
pathway related to fas. Most previous studies of LN metas-
tasis have used experimental systems based on human xe-
nografts formed in immunocompromised mice. Given the 
relevance of immune function to LN metastasis, we consider 
MHX10/Mo/lpr mice to be a superior model system to immu-
nocompromised mice.
The present study examined the effects of 5‐FU, which 
inhibits DNA synthesis by restricting the availability of thy-
midylate during the S phase of the cell cycle.42 Our previous 
investigations utilized cisplatin, a platinum‐containing com-
pound belonging to the alkylating agent family,23,43,44 and 
doxorubicin, which inhibits the progression of an enzyme 
(topoisomerase II) that relaxes DNA supercoils involved in 
transcription.26 Both cisplatin and doxorubicin were effective 
in the treatment of metastatic LNs when administered using 
a LDDS, indicating that conventional drugs used in the clinic 
have the potential to treat metastatic LNs when administered 
with this novel approach. A potential important advantage 
of a LDDS over systemic chemotherapy is that treatment 
of a metastatic LN requires much smaller quantities of drug 
(1/100 to 1/10 000 of the amount), which would minimize 
side effects due to drug administration (Table 1).23,26,43,44 
This finding strongly indicates that drug administration with 
a LDDS would likely not be associated with serious adverse 
events. We anticipate that the effectiveness of drug admin-
istration with a LDDS in the treatment and prevention of 
false‐negative metastatic LNs will be evaluated further in fu-
ture clinical trials.
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